Skip to main content

Kintz Samuel's Form 4 filing

Enliven Therapeutics, Inc. (ELVN) · filed Dec 26, 2023

Accession no.
0001209191-23-059717
Filed
Dec 26, 2023
Trade date
Dec 21-22, 2023
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $106.9K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kintz SamuelCIK 0001967168Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 21, 2023Common StockMOption exerciseAcquired+20$1.12+$22.420Direct
Dec 21, 2023Common StockSSaleDisposed−20$13.00−$2600Direct
Dec 22, 2023Common StockMOption exerciseAcquired+8,175$1.12+$9,1568,175Direct
Dec 22, 2023Common StockSSaleDisposed−8,175$13.05F2−$106,683.750Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 21, 2023Common StockMOption exerciseDisposed−20$0.00$0316,725Direct
Dec 22, 2023Common StockMOption exerciseDisposed−8,175$0.00$0308,550Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $13.00 to $13.2813. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)